Table 1

Patient demographic data, disease activity scores (DAS28), and fatigue scores (FACIT fatigue)

Patient number

Age (years)

Rheumatoid factor status

Disease duration (years)

Concurrent DMARD

Concurrent corticosteroid NSAID or COX2

DAS 28 pre-adalimumab

DAS 28 after 3 months of adalimumab

FACIT fatigue pre-adalimumab

FACIT fatigue after 3 months of adalimumab

1

49

+

13

leflunomide

diclofenac

7.38

2.84

15

33

2

43

+

7

none

celecoxib

7.42

3.88

2

46

3

57

-

14

Methotrexate leflunomide

celecoxib

6.37

3.41

22

45

4

60

+

4

none

celecoxib

6.32

2.59

46

44

5

44

-

9

none

none

6.36

4.36

9

25

6

37

+

17

methotrexate

naproxen

6.33

4.50

11

20

7

39

+

13

methotrexate

diclofenac

6.56

3.53

17

43

8

39

-

18

methotrexate

indomethacin

6.25

4.46

25

33

9

61

-

12

none

none

6.01

2.16

26

47

10

52

-

12

sulfasalazine

none

7.37

2.95

18

39

11

49

-

13

methotrexate

none

6.29

5.41

16

36

12

53

+

10

leflunomide

diclofenac

8.20

4.49

15

24

13

53

+

13

none

none

5.11

5.11

40

41

COX2, Cyclooxygenase-2 inhibitor; DMARD, disease-modifying anti-rheumatic drug; NSAID, non-steroidal anti-inflammatory drug.

Raftery et al. Arthritis Research & Therapy 2012 14:R263   doi:10.1186/ar4108